3D microscopy magnifies understanding of body's immune response to obesity

A new analytical technique is allowing scientists are getting a clearer view of the microenvironments found within adipose tissue associated with obesity. This advance may illuminate why some adipose tissues are more prone to inflammation - leading to diseases like type 2 diabetes, cancer and cardiovascular disorders - and help direct future drug therapies to treat obesity.

Prolonged sedentary time to linked distractibility in adults with obesity and overweight

Scientists used accelerometers to track daily activity levels for a week in 89 adults with obesity or overweight and, in a series of tests, measured their ability to multitask and maintain their attention despite distractions. The study revealed that individuals who spent more sedentary time in bouts lasting 20 minutes or more were less able to overcome distractions.

Body shape determines fat stigma for women

Scientists from Arizona State University and Oklahoma State University have reported that not all overweight and obesity body shapes are equally stigmatised. Unfortunately, fat stigma is a socially acceptable form of prejudice that contributes to poor medical outcomes and negatively affects educational and economic opportunities. This latest study has shown that women with abdominal fat around their midsection are more stigmatised than those with gluteofemoral fat on the hips, buttocks and thighs.

Prediabetes may be linked to cognitive decline

Researchers from UCL Institute of Cardiovascular Science and the UCL MRC Unit for Lifelong Health & Ageing, London, UK, who analysed data from the UK Biobank of 500,000 people aged 58 years on average, found that people with higher than normal blood sugar levels were 42% more likely to experience cognitive decline over an average of four years. They were also 54% more likely to develop vascular dementia over an average of eight years, although absolute rates of both cognitive decline and dementia were low.

INSPIRE: Revita DMR plus GLP-1RA shows durable insulin-free glycaemic control

Outcomes form the investigator-initiated INSPIRE clinical trial, conducted in collaboration with Fractyl, have demonstrate that a majority of patients with type 2 diabetes treated with a combination of Revita DMR (duodenal mucosal resurfacing) and a glucagon-like peptide-1 receptor agonist (GLP-1RA) were able to discontinue and remain off insulin therapy for 18 months after treatment. Additionally, all treated patients showed significant improvements in measures of glucose regulation and metabolic health.

'Unsubstantiated’ fears about sweeteners adding to diabesity epidemic

Confusion and misunderstanding still surrounds artificial sweeteners and it is harming the fight against obesity and diabetes, according to research led by Liverpool Hope University, UK. The investigators are calling for an education campaign to improve the reputation of non-nutritive sweeteners in order to get more people making the sugar-sweetener swap. 

Chinese people maybe more susceptible to obesity-related health risks

Chinese people are more likely to face high blood pressure and other health risks as a result of higher body mass index (BMI) and waist circumference than people from other racial and ethnic groups, according to a researchers from the Shanghai Jiaotong University School of Medicine in Shanghai, China. The findings were reported in the paper, ‘Chinese Adults Are More Susceptible to Effects of Overall Obesity and Fat Distribution on Cardiometabolic Risk Factors’, published in Journal of Clinical Endocrinology & Metabolism

Obesity and excess body fat associated mortality exceeds smoking mortality

Obesity and excess body fat may have contributed to more deaths in England and Scotland than smoking since 2014, according to research led by the University of Glasgow. Between 2003 and 2017 the percentage of deaths attributable to smoking are calculated to have decreased from 23.1% to 19.4% while deaths attributable to obesity and excess body fat are calculated to have increased from 17.9% to 23.1%.

STEP outcomes: Semaglutide could be ‘gamechanger’ in battle against obesity

One third (35%) of patients who received semaglutide for treating obesity lost more than one-fifth (greater than or equal to 20%) of their total body weight, according to the outcomes from the ‘Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity’ (STEP 1) randomised clinical trial. The findings reported in the paper, ‘Once-Weekly Semaglutide in Adults with Overweight or Obesity’, from the large-scale international trial were published in the New England Journal for Medicine.

Sensitivity to sweet taste predicts weight loss from bariatric surgery

Bariatric surgery leads to greater weight loss in patients who had a heightened perception of sweetness before surgery, according to a study led by scientists from the Champalimaud Centre for the Unknown, in Lisbon, Portugal. They claim that their study shows, for the first time, that preoperative sweet intensity predicts weight loss after surgery and that post-surgery changes in this variable track the amount of weight loss in each patient.

Dynatronics launches Bariatric Electric Stand-In Table with Patient Lift

Dynatronics has introduced a new bariatric stand-in table with motorised patient lift and a laminated H-brace treatment table. The Bariatric Electric Stand-In Table with Patient Lift (Hausmann Model 6177) is a motorised variable-height stand-in table with the ability to lift a 500lb patient from a sitting position to a standing position (this model replaces a previously discontinued model).

Excess weight contributes disproportionally to the costs of COVID‐19

A healthcare cost model study that was designed to estimate the total secondary care costs of patients by body mass index (BM) category - when hospitalised due to COVID‐19 in Europe (during the first wave of the pandemic from January to June 2020) - has reported excess weight contributed disproportionally to the costs of COVID‐19. The outcomes were reported in the paper, ‘Costs of the COVID‐19 pandemic associated with obesity in Europe: A health‐care cost model’, published in Clinical Obesity.

First patient dosed in trial of Apraglutide for short bowel syndrome

The first patient has been dosed in its pivotal phase 3 trial of apraglutide in short bowel syndrome (SBS). Apraglutide is an investigational drug being developed as a once-weekly treatment for patients who have SBS with intestinal failure (SBS-IF). It is a next-generation, long-acting, potent, synthetic GLP-2 analog that acts as a selective, full agonist of the GLP-2 receptor.

Karl Storz launches IMAGE1 S Rubina multimode visualisation system

Karl Storz Endoscopy-America has launched the IMAGE1 S Rubina multimode visualisation system that combines state-of-the-art 4K resolution with enhanced fluorescence-guided imaging using near-infrared light and indocyanine green dye (NIR/ICG). The system uses unique and proprietary dual-4K sensors and dual-LED light technology to toggle seamlessly between white-light and fluorescence modes, without the lag or mismatched frames that are common with alternative technologies.

RCT to assess two exercise programme in bariatric patients

Chilean researchers have initiated a randomised clinical trial (RCT) to assess the effects of two types of exercise - moderate-intensity continuous training (MICT) and high-intensity interval training (HIIT) - on body composition, cardiopulmonary function and perceived quality of life in bariatric surgery patients. An outline of the study was featured in the paper, ‘Effect of physical exercise in bariatric surgery patients: protocol of a randomized controlled clinical trial’, published in BMC Trials.